EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Oritavancin as consolidation or suppressive therapy in infective endocarditis and device-related infections: real-world experience with therapeutic drug monitoring

Simone Giuliano, Luca Martini iD, Maria Merelli iD, Giulia Turicchi, Jacopo Angelini, Sara Ferin, Antonio D'avolio, Paolo Gaibani iD, Marco Bongiovanni iD, Carlo Tascini iD

JAC-Antimicrobial Resistance · 02.07.2026 · 8 (4)

DOI: 10.1093/jacamr/dlag150 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 24.07.2026. Verfasst von Simone Giuliano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Division, Department of Medicine (DMED), University of Udine and Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, …. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oritavancin is a long-acting semisynthetic lipoglycopeptide with potent activity against a broad range of Gram-positive pathogens. Its multimodal mechanism of action and prolonged terminal half-life allow for extended dosing intervals, making it an off-label option for invasive infections requiring long-term antimicrobial exposure. However, evidence supporting its use in infective endocarditis and cardiac device–related infections remain limited.

Methods

We performed a retrospective multicentre observational study including adult patients treated with multidose oritavancin for infective endocarditis and cardiac device-related infections between 2020 and 2025. Oritavancin was administered as consolidation or as long-term suppressive therapy. Demographic, clinical, microbiological, pharmacological, and outcome data were collected. Therapeutic drug monitoring was performed, and pre-dose plasma concentrations were analysed. Clinical outcomes included clinical cure, microbiological failure, adverse events, and 30- and 90-day all-cause mortality.

Results

Nine patients were included. Oritavancin was mainly administered at 1200 mg per dose, with a median dosing interval of 10 days. Clinical success was achieved in 6/9 patients (66.7%). One patient discontinued therapy due to infusion-related adverse events, and two experienced microbiological failure, both in left ventricular assist device-related infections. No 30- or 90-day mortality was observed. TDM, when performed, demonstrated persistent pre-dose plasma concentrations over several weeks, with marked interindividual variability across patients and intra-individual temporal changes over time, including drug accumulation in some cases.

Conclusion

Multidose oritavancin appears to be a promising consolidation or suppressive strategy in selected patients with complex Gram-positive endovascular infections. Prospective studies are needed to define optimal dosing regimens and the role of TDM in this setting.

Autor:innen und Institutionen

  • Infectious Diseases Division, Department of Medicine (DMED), University of Udine and Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy.
  • Division of Infectious Diseases, Ente Ospedaliero Cantonale, Lugano Hospital, Lugano, Switzerland.
  • Clinical Pharmacology and Toxicology Institute, University Hospital Friuli Centrale ASUFC, Udine 33100, Italy.
  • Department of Medicine (DMED), University of Udine and Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy.
  • Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin-ASL 'Città di Torino', Turin, Italy.
  • Department of Diagnostic and Public Health, University of Verona, Verona, Italy.

ORCID-Profile: Luca Martini, Maria Merelli, Paolo Gaibani, Marco Bongiovanni, Carlo Tascini

Zitieren

APA

Giuliano, S., Martini, L., Merelli, M., Turicchi, G., Angelini, J., Ferin, S., D'avolio, A., Gaibani, P., Bongiovanni, M., & Tascini, C. (2026). Oritavancin as consolidation or suppressive therapy in infective endocarditis and device-related infections: real-world experience with therapeutic drug monitoring. JAC-Antimicrobial Resistance, 8(4). https://doi.org/10.1093/jacamr/dlag150

Vancouver

Giuliano S, Martini L, Merelli M, Turicchi G, Angelini J, Ferin S, et al. Oritavancin as consolidation or suppressive therapy in infective endocarditis and device-related infections: real-world experience with therapeutic drug monitoring. JAC-Antimicrobial Resistance. 2026;8(4). doi:10.1093/jacamr/dlag150

BibTeX
@article{Giuliano2026,
  author = {Giuliano, Simone and Martini, Luca and Merelli, Maria and Turicchi, Giulia and Angelini, Jacopo and Ferin, Sara and D'avolio, Antonio and Gaibani, Paolo and Bongiovanni, Marco and Tascini, Carlo},
  title = {Oritavancin as consolidation or suppressive therapy in infective endocarditis and device-related infections: real-world experience with therapeutic drug monitoring},
  journal = {JAC-Antimicrobial Resistance},
  year = {2026},
  volume = {8},
  number = {4},
  doi = {10.1093/jacamr/dlag150}
}
Kostenlos starten →